Preexisting antitumor immunity augments the antitumor effects of chemotherapy

Cancer Immunology, Immunotherapy

Volumn 62, Issue 6, 2013, Pages 1061-1071

  Zhang, Lingbing ^a   Feng, Dongdong ^a   Yu, Lynda X ^a   Tsung, Kangla ^a   Norton, Jeffrey A ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Chemotherapy; Dendritic cells; Immunity; Interleukin 12; Preexisting

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; GAMMA INTERFERON; GEMCITABINE; RECOMBINANT INTERLEUKIN 12; T LYMPHOCYTE RECEPTOR; TUMOR ANTIGEN; VINBLASTINE;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CHEMOTHERAPY; CELLULAR IMMUNITY; COCULTURE; CONTROLLED STUDY; CYTOKINE RELEASE; DENDRITIC CELL; FEMALE; MOUSE; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; T LYMPHOCYTE; TUMOR IMMUNITY; TUMOR REGRESSION;

ANIMALS; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; IMMUNITY; MICE; MICE, KNOCKOUT; NEOPLASMS; T-LYMPHOCYTES; TREATMENT OUTCOME;

EID: 84878874815     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-013-1417-7     Document Type: Article

References (27)

1. MacKie RM, Reid R, Junor B (2003) Fatal melanoma transferred in a donated kidney 16 years after melanoma surgery. N Engl J Med 348(6):567-568
2. Gribben JG, Ryan DP, Boyajian R, Urban RG, Hedley ML, Beach K, Nealon P, Matulonis U, Campos S, Gilligan TD, Richardson PG, Marshall B, Neuberg D, Nadler LM (2005) Unexpected association between induction of immunity to the universal tumor antigen CYP1B1 and response to next therapy. Clin Cancer Res 11(12):4430-4436
3. Halama N, Michel S, Kloor M, Zoernig I, Benner A, Spille A, Pommerencke T, von Knebel DM, Folprecht G, Luber B, Feyen N, Martens UM, Beckhove P, Gnjatic S, Schirmacher P, Herpel E, Weitz J, Grabe N, Jaeger D (2011) Localization and density of immune cells in the invasive margin of human colorectal cancer liver metastases are prognostic for response to chemotherapy. Cancer Res 71(17):5670-5677
4. Dunn GP, Old LJ, Schreiber RD (2004) The immunobiology of cancer immunosurveillance and immunoediting. Immunity 21(2):137-148
5. North RJ, Bursuker I (1984) Generation and decay of the immune response to a progressive fibrosarcoma. I. Ly-1 + 2-suppressor T cells down-regulate the generation of Ly-1-2+ effector T cells. J Exp Med 159(5):1295-1311
6. Klebanoff CA, Gattinoni L, Restifo NP (2006) CD8+ T-cell memory in tumor immunology and immunotherapy. Immunol Rev 211:214-224
7. Lake RA, Robinson BW (2005) Immunotherapy and chemotherapy - a practical partnership. Nat Rev Cancer 5(5):397-405
8. Dong Xda E, Ito N, Lotze MT, Demarco RA, Popovic P, Shand SH, Watkins S, Winikoff S, Brown CK, Bartlett DL, Zeh HJ III (2007) High mobility group box I (HMGB1) release from tumor cells after treatment: implications for development of targeted chemoimmunotherapy. J Immunother 30(6):596-606
9. Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, Criollo A, Mignot G, Maiuri MC, Ullrich E, Saulnier P, Yang H, Amigorena S, Ryffel B, Barrat FJ, Saftig P, Levi F, Lidereau R, Nogues C, Mira JP, Chompret A, Joulin V, Clavel-Chapelon F, Bourhis J, André F, Delaloge S, Tursz T, Kroemer G, Zitvogel L (2007) Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 13(9):1050-1059
10. Tong Y, Song W, Crystal RG (2001) Combined intratumoral injection of bone marrow-derived dendritic cells and systemic chemotherapy to treat pre-existing murine tumors. Cancer Res 61(20):7530-7535
11. Yu B, Kusmartsev S, Cheng F, Paolini M, Nefedova Y, Sotomayor E, Gabrilovich D (2003) Effective combination of chemotherapy and dendritic cell administration for the treatment of advanced-stage experimental breast cancer. Clin Cancer Res 9(1):285-294
12. Nikitina EY, Gabrilovich DI (2001) Combination of gamma-irradiation and dendritic cell administration induces a potent antitumor response in tumor-bearing mice: approach to treatment of advanced stage cancer. Int J Cancer 94(6):825-833
13. Udagawa M, Kudo-Saito C, Hasegawa G, Yano K, Yamamoto A, Yaguchi M, Toda M, Azuma I, Iwai T, Kawakami Y (2006) Enhancement of immunologic tumor regression by intratumoral administration of dendritic cells in combination with cryoablative tumor pretreatment and Bacillus Calmette-Guerin cell wall skeleton stimulation. Clin Cancer Res 12(24):7465-7475
14. Tsung K, Meko JB, Tsung YL, Peplinski GR, Norton JA (1998) Immune response against large tumors eradicated by treatment with cyclophosphamide and IL-12. J Immunol 160(3):1369-1377
15. Le HN, Lee NC, Tsung K, Norton JA (2001) Pre-existing tumor-sensitized T cells are essential for eradication of established tumors by IL-12 and cyclophosphamide plus IL-12. J Immunol 167(12):6765-6772
16. Awwad M, North RJ (1988) Immunologically mediated regression of a murine lymphoma after treatment with anti-L3T4 antibody. A consequence of removing L3T4+ suppressor T cells from a host generating predominantly Lyt-2+ T cell-mediated immunity. J Exp Med 168(6):2193-2206
17. Ghiringhelli F, Larmonier N, Schmitt E, Parcellier A, Cathelin D, Garrido C, Chauffert B, Solary E, Bonnotte B, Martin F (2004) CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. Eur J Immunol 34(2):336-344
18. Vincent J, Mignot G, Chalmin F, Ladoire S, Bruchard M, Chevriaux A, Martin F, Apetoh L, Rébé C, Ghiringhelli F (2010) 5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. Cancer Res 70(8):3052-3061
19. Suzuki E, Kapoor V, Jassar AS, Kaiser LR, Albelda SM (2005) Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clin Cancer Res 11(18):6713-6721
20. North RJ, Awwad M (1990) Elimination of cycling CD4+ suppressor T cells with an anti-mitotic drug releases non-cycling CD8+ T cells to cause regression of an advanced lymphoma. Immunology 71(1):90-95
21. Ruby CE, Montler R, Zheng R, Shu S, Weinberg AD (2008) IL-12 is required for anti-OX40-mediated CD4 T cell survival. J Immunol 180(4):2140-2148
22. Galluzzi L, Senovilla L, Zitvogel L, Kroemer G (2012) The secret ally: immunostimulation by anticancer drugs. Nat Rev Drug Discov 11(3):215-233
23. Zitvogel L, Kroemer G (2011) Anticancer effects of imatinib via immunostimulation. Nat Med 17(9):1050-1051
24. Kroemer G, Galluzzi L, Kepp O, Zitvogel L (2012) Immunogenic cell death in cancer therapy. Annu Rev Immunol 31:51-72
25. Zitvogel L, Kroemer G (2009) Anticancer immunochemotherapy using adjuvants with direct cytotoxic effects. J Clin Invest 119(8):2127-2130
26. Novak AK, Robinson BWS, Lake RA (2002) Gemcitabine exerts a selective effect on the humoral immune response: implications for combination chemo-immunotherapy. Cancer Res 62(8):2353-2358
27. Tsung K, Dolan JP, Tsung YL, Norton JA (2002) Macrophages as effector cells in interleukin 12-induced T cell-dependent tumor rejection. Cancer Res 62(17):5069-5075